1. Home
  2. Live Updates
  3. Pulmonary arterial

Live Breaking News & Updates on Pulmonary arterial

Stay informed with the latest breaking news from Pulmonary arterial on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pulmonary arterial and stay connected to the pulse of your community

New Drug Helps Patients With High Blood Pressure of the Lungs Breathe Easier

The FDA has approved sotatercept (Winrevair), a first-in-kind drug to improve exercise tolerance and functional class and slow the progression of pulmonary arterial hypertension.

Michigan , United-states , Heather-kauffman , Vallerie-mclaughlin , Nick-blackmer , Verywell-health , University-of-michigan-health , Drug-administration , Pulmonary-arterial , Michigan-health , New-type , Pulmonary-hypertension

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 -- Inhibikase Therapeutics, Inc. , a...

Boston , Massachusetts , United-states , Atlanta , Georgia , Alex-lobo , Miltonh-werner , Milton-werner , Inhibikase-therapeutics-inc , Nasdaq , Drug-administration , Stern-investor-relations-inc

Inhibikase Announces Pre-IND Meeting For IkT-001Pro

Inhibikase Therapeutics, Inc. (IKT) announced it will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the FDA for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension.

Milton-werner , More-such-health-news , Inhibikase-therapeutics-inc , Division-of-cardiology , Office-of-cardiology , Inhibikase-therapeutics , Pulmonary-arterial , Pulmonary-arterial-hypertension , Fda , Nhibikase- ,

Celebrating the Most Expensive Drug for the Disease You Never Heard Of & More - This Week in RARE Daily

Celebrating the Most Expensive Drug for the Disease You Never Heard Of & More - This Week in RARE Daily
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

Ottawa , Ontario , Canada , Merck-winrevair , Global-genes , Most-expensive-drug , Disease-you-never-heard , Pulmonary-arterial , Unlock-genetics , Ultra-rare-neurodevelopmental , Borjeson-forssman-lehmann-syndrome

FDA Approves Johnson & Johnson OPSYNVI (macitentan and tadalafil) Single-Tablet Combination for Patients with Pulmonary Arterial Hypertension (PAH)

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension (PAH). The newly-approved drug is a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.

United-states , American , Johnson , Kelly-chin , Pulmonary-hypertension-program , American-lung-association , Ut-southwestern-medical-center , European-respiratory-society , European-society-of-cardiology , Actelion-pharmaceuticals-us-inc , Drug-administration , World-health-organization-group

FDA Drug Approval Decisions Expected in March 2024

The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.

Atidarsagene-autotemcel , Drug-administration , Prescription-drug-user-fee-act , New-drug-application , Biologics-license-application , Priority-review , Nonalcoholic-steatohepatitis , With-liver , Pulmonary-arterial , Anemia-due , Chronic-kidney ,

Top 5 Most-Read PAH Content of 2023

This year’s top 5 most-read articles on pulmonary arterial hypertension (PAH) explored expert opinions on treatment approaches, data on newly emerging therapies, the impacts of alcohol, and more.

Louisiana , United-states , New-orleans , Institute-for-clinical , American-college-of-cardiology , May-yield-more-favorable , Patients-with , Evidence-needed , Right-heart-imaging , Review-sotatercept , Pulmonary-arterial

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , Tim-noyes , Nasdaq , Linkedin , Aerovate-therapeutics-inc , Exchange-commission , Twitter , Therapeutics-announces-simultaneous-completion , First-patient , Pulmonary-arterial , Chief-executive-officer , Aerovate-therapeutics

Pulmonary Drugs Market Worth $136.27 Billion By 2030, Growing At A CAGR Of 8.16% - Exclusive Report By 360Iresearch

Pulmonary Drugs Market Worth $136.27 Billion By 2030, Growing At A CAGR Of 8.16% - Exclusive Report By 360Iresearch
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Taiwan , Germany , Indonesia , Nigeria , India , Poland , Vietnam , Republic-of , Denmark , Malaysia , Turkey , Australia

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Nov 9, 2023--

United-states , California , Stanford-university , America , Roham-zamanian , Asia-pacific , Bryan-giraudo , Faheem-hasnain , Development-rd-expenses , Gossamer-bio-inc , Exchange-commission , Critical-care-medicine-at-stanford-university